Exenatide Exenatide (Byetta), an incretin mimetic, is FDA approved for use as adjunctive therapy in patients whose T2DM is inadequately controlled with metformin, an SU, a TZD, or with combination of metformin plus an SU or TZD
References Proposed Rule Would Expand Medicare And Medicaid Coverage For Anti-Obesity Medications | Health Affairs CMSs $40B GLP-1 Proposal Offers Leeway for Part D Plans to Define Obe AIS Health - MMIT Medicare & Medicaid Services CMS Proposes Changes to Medicare Adv Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Rosenstock J, Frias J, Jastreboff AM, et al
This RWD includes: Patient-reported outcomes and engagement metrics Adherence patterns and digital biomarker data Insights into motivations, behaviors and lifestyle factors Uncover predictors of stay time and treatment response These data points help identify treatment response patterns and ensure patients receive the right intervention at the right time, enhancing the overall effectiveness of obesity care
Patients should be advised to contact their GP urgently if hair loss is accompanied by scalp pain, redness, scaling, or loss of follicular openings, as these may indicate scarring alopecia requiring prompt dermatological assessment
